

Stenorol[®] CRYPTO



Effective against Cryptosporidiosis
in calves

- ▶ 0.50 mg/ml of halofuginone base (as lactate)
- ▶ Solution for use in drinking water for calves



Stenorol® CRYPTO

0.5 mg/ml halofuginone base (as lactate salt) oral solution for calves

Composition

Each ml contains:

0.50 mg/ml of halofuginone base (as lactate)

Target species

New born calves

Indications

In new born calves:

Prevention of diarrhoea due to diagnosed *Cryptosporidium parvum*, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age.

Reduction of diarrhea due to diagnosed *Cryptosporidium parvum*. Administration should start within 24 hours after the onset of diarrhoea.

Dosage and treatment period

For oral use in calves after feeding. 2 ml **Stenorol® CRYPTO**/10 kg BW/per day, for 7 days

For similar or higher weights, a precise calculation should be performed (2 ml/10 kg).

To ensure a correct dosage, the use of either a syringe or any appropriate device for oral administration is necessary. The consecutive treatment should be done at the same time each day.

Once the first calf has been treated, all the forthcoming new-born calves must be systematically treated as long as the risk for diarrhoea due to *C. parvum* persists.

Withdrawal period(s)

Meat and offal: **13 days.**

Shelf life and storage

Shelf-life of the veterinary medicinal product as packaged for sale: 24 months

Shelf-life after first opening of the immediate packaging: 6 months

Packaging

Plastic bottles of 500 ml and 1 L

Not all pack sizes may be marketed

Contraindications

Do not use on an empty stomach.

Do not use in case of diarrhea established for more than 24 hours and in weak anim.



Special precautions for use in animals: administer after colostrum feeding, or after milk or milk replacer feeding only, using either a syringe or any appropriate device for oral administration. Do not use on an empty stomach. For treatment of anorexic calves, the product should be administered in half a liter of an electrolyte solution. The animals should receive enough colostrum according to good breeding practice. **Special precautions to be taken by the person administering the medicinal product to animals:** this product contains halofuginone, which can cause allergic reactions in some people. The product may be irritating to the skin and eyes and systemic toxicity cannot be excluded in case of contact with the skin. People with known hypersensitivity (allergy) to halofuginone or any of the excipients should administer the veterinary medicinal product with caution. Repetitive contact with the product may lead to skin allergies. Avoid skin, eye or mucosal contact with the product. Wash hands after use. **Other precautions:** none. **Adverse reactions (frequency and seriousness):** in very rare cases, an increase in the level of diarrhea has been observed in treated animals. **Use during pregnancy, lactation or lay:** not applicable. **Interaction with other medicinal products and other forms of interaction:** none known. **Overdose (symptoms, emergency procedures, antidotes), if necessary:** symptoms of toxicity may occur at twice the therapeutic dose, it is necessary to apply the recommended dosage strictly. Symptoms of toxicity include diarrhea, visible blood in feces, decline in milk consumption, dehydration, apathy and prostration. Should clinical signs of overdosing occur the treatment must be stopped immediately and the animal fed milk or milk replacer. Rehydration may be necessary.

Huvepharma EOOD. 3a Nikolay Haytov Str, 1113 Sofia, Bulgaria.
Tel +359 2 862 5331. sales@huvepharma.com

Huvepharma N.V. Uitbreidingstraat 80, 2600 Antwerp, Belgium.
Tel +32 3 288 1849. customerservice@huvepharma.com

